SCHEMBL1378518

SCHEMBL1378518

Cc1ccc(F)c(NC(=O)Nc2ccc(-c3csc4c(-c5ccncc5)cnc(N)c34)cc2)c1

nearest known ligand 0.79

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDR P35968 17/20 0.79
AURKB Q96GD4 10/20 0.79
FLT1 P17948 9/20 0.79
CSF1R P07333 8/20 0.79
LYN P07948 8/20 0.79
KIT P10721 8/20 0.79
BLK P51451 8/20 0.79
PLK4 O00444 7/20 0.79
AURKA O14965 7/20 0.79
ABL1 P00519 7/20 0.79
NTRK1 P04629 7/20 0.79
MET P08581 7/20 0.79
FGFR1 P11362 7/20 0.79
NEK2 P51955 7/20 0.79
STK3 Q13188 7/20 0.79
ROCK1 Q13464 7/20 0.79
NTRK2 Q16620 7/20 0.79
LCK P06239 7/20 0.79
SRC P12931 7/20 0.79
FYN P06241 7/20 0.79

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3532643 0.94 KDR (0.75) KDRAURKBFLT1CSF1RLYN
SCHEMBL1379004 0.93 KDR (0.77) KDRAURKBFLT1CSF1RLYN
SCHEMBL3530388 0.93 PLK4 (0.76) KDRAURKBFLT1CSF1RLYN
SCHEMBL3534099 0.91 KDR (0.76) KDRAURKBFLT1CSF1RLYN
SCHEMBL3526057 0.90 PLK4 (0.71) KDRAURKBFLT1CSF1RLYN
SCHEMBL3532104 0.90 PLK4 (0.71) KDRAURKBFLT1CSF1RLYN
SCHEMBL3526685 0.90 KDR (0.80) KDRAURKBFLT1CSF1RLYN
SCHEMBL3528193 0.89 PLK4 (0.70) KDRAURKBFLT1CSF1RLYN
SCHEMBL3530181 0.89 FLT1 (0.68) KDRAURKBFLT1CSF1RLYN
SCHEMBL3529804 0.88 KDR (1.00) KDRAURKBFLT1CSF1RLYN

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
JP-4707192-B2 2011-06-22 JP claimed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US claimed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP claimed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US claimed
EP-1648905-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS Abbott Laboratories (US) 2006-04-26 EP claimed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US claimed
WO-2005010009-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2005-02-03 WO claimed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US claimed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 US claimed
US-8273736-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2012-09-25 US disclosed
US-7737160-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES INC. (US) 2010-06-15 US disclosed
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LABORATORIES (US) 2010-03-18 US disclosed
EP-1648905-B1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBOTT LAB (US) 2008-12-31 EP disclosed
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABBVIE INC. 2007-07-05 US disclosed
US-7202363-B2 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES (US) 2007-04-10 US disclosed
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABBVIE INC. 2005-02-24 US disclosed
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABBOTT LABORATORIES 2005-02-03 US disclosed
US-20050020619-A1 Thienopyridine kinase inhibitors ABBOTT LABORATORIES 2005-01-27 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20050020619-A1 Thienopyridine kinase inhibitors ABL1, MAP4K2, MAP4K5 KDR 511/4885AURKB 262/4885FLT1 891/4885
US-20050026944-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20050043347-A1 Thienopyridine and furopyridine kinase inhibitors ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20100069371-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885
US-20070155776-A1 THIENOPYRIDINE AND FUROPYRIDINE KINASE INHIBITORS ABL1, ERBB2, LCK KDR 494/4885AURKB 171/4885FLT1 613/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.